Ocean Biomedical, Inc.

Equities

OCEA

US67644C1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 08/06/2024 am IST			5-day change	1st Jan Change
1.445 ^USD	-0.69%		-1.70%	+118.94%

30/05	Ocean Biomedical Gets Nasdaq Noncompliance Notice; Shares Down	MT
15/04	Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Ocean Biomedical, Inc. Announces Resignation of Jerome Ringo as Member of Board of Directors

October 13, 2023 at 02:40 am IST

On October 6, 2023, Jerome Ringo resigned as a member of Ocean Biomedical?s board of directors. Mr. Ringo?s resignation is not the result of any dispute or disagreement with Ocean Biomedical or the board of directors on any matter relating to the operations, policies, or practices of Ocean Biomedical.

Latest news about Ocean Biomedical, Inc.

Ocean Biomedical Gets Nasdaq Noncompliance Notice; Shares Down	30/05	MT
Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/04	CI
Ocean Biomedical, Inc. Appoints Amy Griffith as Director	09/03	CI
Ocean Biomedical, Inc. Announces CFO Changes	05/03	CI
North American Morning Briefing : S&P 500 Futures -2-	23/02	DJ
North American Morning Briefing : Central Bankers -2-	17/01	DJ
North American Morning Briefing : Stocks to -2-	10/01	DJ
North American Morning Briefing : Stock Futures Extend Losses as FOMC Minutes Awaited	03/01	DJ
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	20/12	DJ
North American Morning Briefing : Traders Await -2-	13/12	DJ
Ocean Biomedical Announces Publication of Breast Cancer Research Uncovering New Tumor Suppression Pathway for its Proprietary Anti-Chi3L1 Antibody	05/12	CI
Ocean Biomedical Receives Non-Compliance Notice From Nasdaq	30/11	MT
North American Morning Briefing : Stock Futures -2-	29/11	DJ
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading	22/11	DJ
Ocean Biomedical Says Potential Treatment for Advanced Solid Tumors Yields 'Highly Compelling' Preclinical Data	14/11	MT
Ocean Biomedical, Inc. Announces Positive Preclinical Oncology Data for Vron 0300, Presented At Sitc 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics	14/11	CI
Virion Therapeutics and Joint Venture Partner, Ocean Biomedical Announces First Patients Dosed with Novel Immunotherapy Evaluating A Functional Cure for Chronic Hepatitis B Virus Infection	26/23/26	CI
Ocean Biomedical, Inc. Announces Resignation of Jerome Ringo as Member of Board of Directors	13/23/13	CI
Ocean Biomedical, Virion Therapeutics Form Joint Venture to Seek Cures for Cancer, Infectious Diseases	12/23/12	MT
Ocean Biomedical, Inc. announced that it expects to receive $10 million in funding from Poseidon Bio, LLC	04/23/04	CI
Ocean Biomedical Says Data Show Antibody Candidate Can Restore Treatment Sensitivity to AstraZeneca's Lung Cancer Drug	03/23/03	MT
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to Astrazeneca?s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers	03/23/03	CI
Ocean Biomedical Secures US Patent for Anti-Chitinase 1 Small Molecule Candidate	29/23/29	MT
Ocean Biomedical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Ocean Biomedical, Inc. Provides Latest Updates on Its Broad Programs in Malaria, Fibrosis, and Multiple Cancers	10/23/10	CI

Chart Ocean Biomedical, Inc.

Duration

Period

More charts

Company Profile

Ocean Biomedical, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The Company helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). It offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
OCEAN BIOMEDICAL, INC.	+118.94%	5.01Cr
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	12TCr
REGENERON PHARMACEUTICALS, INC.	+14.19%	11TCr
BIONTECH SE	-4.93%	2.42TCr
ARGENX SE	+3.23%	2.28TCr
GENMAB A/S	-10.44%	1.8TCr
WUXI APPTEC CO., LTD.	-41.74%	1.64TCr
BEIGENE, LTD.	-13.31%	1.64TCr
NEUROCRINE BIOSCIENCES, INC.	+2.44%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+27.89%	1.17TCr

Bio Therapeutic Drugs